GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting

SHANGHAI and CHICAGO, June 2, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in

Related Keywords

Thailand ,Chicago ,Illinois ,United States ,China ,Candiolo ,Piemonte ,Italy ,Shanghai ,Yu Wang ,Henan ,American ,Vanesa Gregorc ,Rafael Rosell ,China National Medical Products Administration ,American Society Of Clinical Oncology ,Candiolo Cancer Institute ,Genfleet Therapeutics ,Clinical Oncology ,National Medical Products Administration ,Chief Medical Officer ,Priority Review Designation ,Breakthrough Therapy Designations ,Thailand Business ,